Onconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022

Rhea-AI Summary

Onconova Therapeutics (NASDAQ: ONTX) announced that it will release its Q1 2022 financial results on May 11, 2022. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on pipeline programs. The company's proprietary multi-kinase inhibitor, narazaciclib, is undergoing Phase 1 trials, while rigosertib is being evaluated in a Phase 1/2a study for patients with KRAS+ non-small cell lung cancer. For details, visit www.onconova.com.

Positive

• Scheduled release of Q1 2022 financial results offers transparency to investors.
• Management to provide updates on pipeline programs during the conference call.
• Ongoing clinical trials for narazaciclib and rigosertib may indicate potential future growth.

Negative

• None.

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, May 11, 2022

NEWTOWN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2022 financial results on Wednesday, May 11, 2022. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs.

Conference Call and Webcast Information

Interested parties who wish to participate in the conference call may do so by dialing (855) 428-5741 for domestic and (210) 229-8823 for international callers and using conference ID 7369861.

Those interested in listening to the conference call via the internet may do so by visiting the investors and media page on the company's website at www.onconova.com and clicking on the webcast link. In addition to the live webcast, a replay will be available on the Onconova website for 90 days following the call.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

When will Onconova Therapeutics release its Q1 2022 financial results?

Onconova Therapeutics will release its Q1 2022 financial results on May 11, 2022.

What time is the Onconova conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on May 11, 2022.

How can I participate in the Onconova Therapeutics conference call?

Participants can dial (855) 428-5741 for domestic calls or (210) 229-8823 for international calls, using conference ID 7369861.

What is the focus of Onconova's clinical trials?

Onconova is focusing on developing anti-cancer agents, with ongoing trials for narazaciclib and rigosertib.

Where can I find more information about Onconova Therapeutics?

More information can be found on Onconova's website at www.onconova.com.